

Summary Report of Consolidated Financial Results

For the Six Months Period ended September 30, 2012



November 9, 2012
TSE/OSE-1st section

Company name: NIPRO CORPORATION

Code No.8086

URL: <http://www.nipro.co.jp/>

Representative: Yoshihiko Sano, President and Representative Director

Contact person: Akihiko Yamabe, Director and General Manager of Accounting Division

TEL: (06)6372-2331

Filing date of quarterly reporting: November 14, 2012

Payment date of cash dividends: December 10, 2012

Supplemental material on quarterly reporting: Yes

Presentation on quarterly results: Yes (for institutional investors and analysts)

(Note: Amounts are truncated to one million yen)

1. Consolidated Results for the Six Months ended September 30, 2012 (From April 1, 2012 to September 30, 2012)

(1) Consolidated Results of Operations (Note: % of change from the same period a year ago)

	Net Sales		Operating Income		Ordinary Income		Net Income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
6 months ended September 30, 2012	117,280	14.5	6,303	(22.8)	4,845	(5.4)	6,608	-
6 months ended September 30, 2011	102,432	8.2	8,168	(9.6)	5,121	(6.4)	457	(81.5)

Note: Comprehensive income 6 months ended September 30, 2012: (5,404) million yen (-%) 6 months ended September 30, 2011: (15,697) million yen (-%)

	Earnings per Share	Diluted Earnings per Share
	Yen	Yen
6 months ended September 30, 2012	38.75	34.95
6 months ended September 30, 2011	3.61	3.16

(2) Consolidated Financial Position

	Total Assets	Net Assets	Equity Ratio
	Millions of yen	Millions of yen	%
6 months ended September 30, 2012	512,057	109,108	20.0
Year ended March 31, 2012	499,686	113,950	22.0

Note: Equity 6 months ended September 30, 2012: 102,201 million yen Year ended March 31, 2012: 109,820 million yen

2. Dividends

	Annual Dividends per Year				
	First-quarter	Second-quarter	Third-quarter	Year-end Dividends	Annual Dividends
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2012	-	12.00	-	11.50	23.50
Year ending March 31, 2013	-	12.00			
Year ending March 31, 2013 (Forecast)			-	8.50	20.50

Note: Revisions to the forecast of cash dividends in the current quarter: Yes

3. Forecast of Consolidated Financial Results for the Year ending March 31, 2013 (From April 1, 2012 to March 31, 2013)

(Note: The % displays in the line of year ending March 31, 2013 show increase/decrease ratio against the year ended March 31, 2012)

	Net Sales		Operating Income		Ordinary Income		Net Income		Earnings per Share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Year ending March 31, 2013	241,000	13.7	13,500	(14.7)	11,500	(4.0)	9,750	112.6	57.17

Note: Revisions to the forecast of consolidated financial results in the current quarter: Yes

*Notes

(1) Change in Significant Subsidiaries during the Current Period
(Change in specified subsidiaries caused a change in the scope of consolidation): No
Additional: 0 Removal: 0

(2) Adoption of Accounting Treatments Simplified or Unique for Preparation: No

(3) Change in Accounting Policies and Accounting Estimate and Restatement

[1] Changes in accounting policies by a newly issued accounting pronouncement	: Yes
[2] Changes other than [1]	: No
[3] Change in accounting estimate	: Yes
[4] Restatement	: No

Note: Depreciation method was changed from the first-quarterly result, which is applied to "Changes in accounting policies which are difficult to distinguish from changes in accounting estimates". Detailed information can be found in P.4 "2. Summary Information (3) Change in Accounting Policies and Accounting Estimate and Restatement" in the attachment.

(4) Issued Shares (Common stock)

[1] Number of issued shares at end of the period (including treasury stock):

6 months ended September 30, 2012 : 171,459,479 shares

Year ended March 31, 2012 : 171,459,479 shares

[2] Number of treasury stock at end of the period:

6 months ended September 30, 2012 : 913,671 shares

Year ended March 31, 2012 : 913,612 shares

[3] Average number of shares during the period :

6 months ended September 30, 2012 : 170,545,858 shares

6 months ended September 30, 2011 : 126,843,790 shares

*Information regarding the quarterly review procedure

This quarterly summary report is exempt from quarterly review procedure based on the Financial Instruments and Exchanges Act. It is under the review procedure process at the time of disclosure of this report.

*Disclaimer regarding projection information including appropriate use of forecasted financial result, and other special notes

The projection figures shown above are based on information that was available at the time of preparation and may contain certain uncertainties. Actual performance and other factors may differ from these projections due to changes in circumstances and other developments. More information concerning these forecasts can be found in P.3 "1. Qualitative Information for the Six Months Period ended September 30, 2012, (3) Qualitative Information Concerning Forecast of Consolidated Financial Results" in the attachment.

Table of Contents

1. Qualitative Information for the Six Months Period ended September 30, 2012.....	2
(1) Qualitative Information Concerning Consolidated Financial Results.....	2
(2) Qualitative Information on the Consolidated Financial Position.....	3
(3) Qualitative Information Concerning Forecast of Consolidated Financial Results.....	3
2. Summary (Other) Information.....	3
(1) Overview of Changes in Significant Consolidated Subsidiaries.....	3
(2) Overview of Accounting Procedure Unique for Preparation of Quarterly Consolidated Financial Statement.....	3
(3) Overview of Changes in Accounting Policies and Accounting Estimate and Restatement.....	4
3. Consolidated Financial Statements.....	5
(1) Quarterly Consolidated Balance Sheets.....	5
(2) Quarterly Consolidated Statements of Income and Quarterly Consolidated Statements of Comprehensive Income.....	7
Quarterly Consolidated Statements of Income.....	7
Quarterly Consolidated Statements of Comprehensive Income.....	7
(3) Quarterly Consolidated Statement of Cash Flows.....	8
(4) Notes Related to Going Concern.....	10
(5) Segment Information.....	10
(6) Notes to Statements of Shareholders' Equity, If Having Significant Variation.....	11

1. Qualitative Information for the Six Months Period ended September 30, 2012

(1) Qualitative Information Concerning Consolidated Financial Results

In the current quarter period under review (quarter ended September 30, 2012), uncertain outlook for the global economy prevailed because the economic stagnation caused by debt crisis has continued in Europe even though American economy showed gradual recovery thanks to an increase of personal consumption based on the progress of household debt adjustment and housing market improvement.

Japanese economy, on the other hand, was slowly recovering with the demand for reconstruction from Great East Japan Earthquake but still under harsh management condition due to flagging export with deceleration of overseas economy and the fixed strong yen.

Under such situation, the Nipro Group continued to work hard to improve our manufacturing and sales bases and increase our sales.

As a result, the consolidated sales in the six-months of fiscal year 2012 increased 14.5% from the same period of the previous year to 117,280 million yen.

As for the profit, consolidated operating income decreased 22.8% from the same period of the previous year to 6,303 million yen because of an increase in selling, general and administrative expenses, and consolidated ordinary income decreased 5.4% from the same period of the previous year to 4,845 million yen due to foreign exchange losses. However, the consolidated net income increased 1,343.5% to 6,608 million yen due to generation of proceeds for sales of investment securities and a decrease in extraordinary losses.

The overviews of the results by segment in the current period are as follows.

[1] Medical Business

Looking at the domestic market, business conditions remained extremely severe because the market competition was intensified due to the effect of revision of medical treatment fee conducted in this April and the reduction of official prices for drugs and medical materials. However, each product group recorded great sales as a result of our aggressive sales activities and improvement of sales efficiency aiming to increase our global share.

Our medical-equipment-related products such as dialysis system and our dialysis-related products such as HDF filter, blood circuits and dialysis pharmaceuticals showed strong growth. The sales of our testing-related products such as glucose analysis device (POCT) and vacuum blood drawing system, enteral-alimentation-related products and injection-transfusion-related products also steadily increased.

Overseas sales, on the other hand, have been affected seriously by appreciation of the yen against the US dollar and euro in the foreign exchange markets, but the sales of dialysis-related products such as dialyzer and system test for diabetes mellitus showed significant increase as a result of our promotion of detailed sales activities for dialysis-related and diabetes-related products in close to medical front. As for the sales expansion, we established new sales base in Myanmar, where the future demand is expected, this June. This September, we acquired Salbego Laboratorio Farmaceutico Ltda, a dialysate manufacturer in Brazil, so as to promote sales activities in dialysis market with a good selection of dialysis products. In addition, India plant started manufacturing from this October, and plants in Indonesia and Bangladesh also proceed the preparation for operation. Under these situations, we will work harder to promote the establishment of our brand image and reinforce our sales system.

As a result, net sales of this business increased 15.6% from the same period of the previous year to 81,380 million yen.

[2] Pharmaceutical Business

This business consists of two main divisions: the Generic Drugs Division, providing low cost and high quality medical drugs, and the Contracted Manufacturing Division, offering high value-added products to meet customer needs.

Sales of generic drugs are expected to grow in line with the market, due in part to a government policy for the dissemination of the market for generic drugs to over 30% by the end of fiscal year 2012. Consequently a number of policies have been implemented to encourage the use of generic products. Major pharmaceutical manufacturers have made a full-scale entry into the Japanese market and foreign generic manufacturers have strengthened their marketing strategies, making the competitive environment surrounding the domestic market more severe.

Under these conditions, we have tried to increase the share of the oral drug through reinforcing our sales promotions to dispensing pharmacies and by the close co-operation with drug wholesalers. In addition, as a result of our detailed information service provided mainly to large hospital, the sales in the current period exceeded the sales in the same period of the previous year.

Looking at sales of our contracted manufacturing business, we have worked hard at realizing a variety of detailed services such as contracted development and supporting high value-added initiatives other than OEM manufacturing of other companies' brand. Contracted sales of generic drugs showed fine growth so that the sales grew steadily in this quarter.

As a result, net sales of this business increased 21.3% from the same period of the previous year to 22,989 million yen.

[3] Materials Business

The sales of material glass tube for ampoule and material glass tube for tube bottles increased from the same period of the previous year thanks to the enforcement of the sales to foreign countries. However, the domestic sales decreased from the same period of the previous year with order decrease because the save electricity campaign in this summer decreased the plant operating hours of domestic processing manufacturers. We also received less order for tube bottles and the sales result remained roughly flat.

Pharmaceutical glass business in China recorded fine growth compared to the same period of the previous year as a result of capital investment and promotion of sales activities. The sales of glass for thermos bottles had grown steadily thanks to the increased demand of glass thermos bottles after the Great East Japan Earthquake, but the demand was getting decreased and the sales decreased as well. As for glass for lighting purpose, the order for material glass tube

for electric lamp decreased due to the decreased operation of domestic automotive manufacturers and also the lineup of electric lamp production was diminished so the sales of glass for lighting purpose decreased from the same period of the previous year.

In the field of pharmaceutical containers, the sales of bags for antimicrobial agent and pre-filled syringes increased steadily as well as rubber stoppers for pharmaceutical and vaccine use and kit form containers.

As for the medical preparation and administration related device, the sales showed good increase with our system suitable for each pharmaceuticals. These systems were provided by both of self-development and joint development with pharmaceutical companies based on our processing techniques for plastics, metal and rubber in order to meet the diverse needs in the medical front. Furthermore, under the restrictive policy for medical cost, we continue to promote contract manufacturing and development cooperating with domestic and foreign pharmaceutical companies in general life cycle management of pharmaceuticals, which includes the development of combination products, systematization for self-injection and modification of dosage form.

As a result, net sales of this business decreased 1.1% from the same period of the previous year to 12,793 million yen.

[4] Other Business

In the other business, the sales from real estate rental income decreased 14.8% from the same period of the previous year to 116 million yen.

(2) Qualitative Information on the Consolidated Financial Position

[1] Analysis concerning the conditions of assets, liabilities and net assets

Total assets increased 12,371 million yen from the end of the previous period to 512,057 million yen. Current assets increased 6,746 million yen mainly due to an increase of 5,574 million yen in notes and accounts receivable-trade, and noncurrent assets increased 5,625 million yen mainly due to an increase of 6,439 million yen in construction in progress.

Total liabilities increased 17,213 million yen from the end of the previous period to 402,949 million yen. Current liabilities increased 4,678 million yen mainly due to an increase of 11,770 million yen in short-term loans payable, and noncurrent liabilities increased 12,535 million yen mainly due to an increase of 11,134 million yen in long-term loans payable.

Total net assets decreased 4,841 million yen from the end of the previous period to 109,108 million yen. Shareholders' equity increased 4,464 million yen and accumulated other comprehensive income decreased 12,084 million yen.

[2] Condition of cash flow

The ending balance of cash and cash equivalents in the period under review increased 106 million yen from the previous year to 79,556 million yen.

(Cash flows from operating activities)

Net cash provided by operating activities was 8,015 million yen. The main accounts of cash inflow were income before income taxes and minority interests, 8,976 million yen and depreciation and amortization, 9,874 million yen. The main accounts of cash outflow were the increase of trade notes and accounts receivable, 5,590 million yen and payment of corporate income tax, 2,987 million yen.

(Cash flows from investing activities)

Net cash used in investing activities was 18,694 million yen. The main accounts of cash outflow were payment into time deposit, 11,094 million yen, and purchase of noncurrent assets, 15,441 million yen. The main account of cash inflow was proceeds from withdrawal of time deposits, 14,279 million yen.

(Cash flows from financing activities)

Net cash provided by financing activities was 10,091 million yen. The main account of cash inflow was proceeds from long-term loans payable, 32,056 million yen. The main account of cash outflow was repayment of long-term loans payable, 18,574 million yen.

(3) Qualitative Information Concerning Forecast of Consolidated Financial Results

As for the world economy in the future, economic stagnation is expected to be continued due to the bad effect from the anxiety about the protracted debt problem in Europe. The domestic economy, on the other hand, will also continue to be sluggish because the capital investment and export will keep decreasing.

In such situation, we will aim to promote our sales performance with a huge selection and high-value added products.

At this moment, the forecast of consolidated financial results for the FY2012 which was published on August 10, 2012 is revised based on the current movement in performance.

2. Summary (Other) Information

(1) Change in Significant Subsidiaries during the Current Period

N/A

(2) Accounting Procedure Unique for Preparation of Quarterly Consolidated Financial Statements:

N/A

(3) Change in Accounting Policies and Accounting Estimate and Restatement

(Changes in accounting policies which are difficult to distinguish from changes in accounting estimates)

Effective from the first quarter of the current fiscal year, the Company and its domestic subsidiaries changes the depreciation method for the relevant tangible assets newly acquired from April 1, 2012 according to the amendment of Corporation Tax Act in Japan.

As a result, consolidated operating income, consolidated ordinary income and consolidated net income increased by 140 million yen for each compared with the previous method.

3. Consolidated Financial Statements

(1) [Quarterly Consolidated Balance Sheets]

(Amount: million yen)

	As of March 31, 2012	As of September 30, 2012
Assets		
Current Assets		
Cash and deposits	95,737	96,317
Notes and accounts receivable-trade	68,641	74,216
Merchandise and finished goods	48,114	49,582
Work in process	8,753	9,231
Raw materials and supplies	14,736	15,716
Deferred tax assets	4,829	4,435
Other	9,983	8,030
Allowance for doubtful accounts	(360)	(347)
Total current assets	250,435	257,182
Noncurrent assets		
Property, plant and equipment		
Buildings and structures	116,878	120,987
Accumulated depreciation and impairment loss	(63,320)	(65,585)
Buildings and structures, net	53,558	55,402
Machinery, equipment and vehicles	142,067	150,359
Accumulated depreciation and impairment loss	(103,263)	(109,811)
Machinery equipment and vehicles, net	38,804	40,548
Land	20,446	21,555
Lease assets	1,680	1,987
Accumulated depreciation	(735)	(908)
Lease assets, net	944	1,079
Construction in progress	26,957	33,396
Other	28,317	29,578
Accumulated depreciation and impairment loss	(23,350)	(24,031)
Other, net	4,967	5,547
Total property, plant and equipment	145,678	157,530
Intangible assets		
Goodwill	11,894	11,230
Lease assets	305	340
Other	6,950	10,025
Total intangible assets	19,151	21,596
Investments and other assets		
Investment securities	71,829	54,568
Deferred tax assets	6,597	12,942
Other	8,954	11,268
Allowance for doubtful accounts	(2,961)	(3,030)
Total investments and other assets	84,420	75,748
Total noncurrent assets	249,250	254,875
Total assets	499,686	512,057

(Amount: million yen)

	As of March 31, 2012	As of September 30, 2012
Liabilities		
Current liabilities		
Notes and accounts payable-trade	37,721	39,317
Short-term loans payable	104,131	115,901
Commercial papers	10,000	—
Current portion of bonds	10,000	10,000
Lease obligations	426	728
Accounts payable-other	6,036	6,374
Accrued directors' bounuses	153	—
Income taxes payable	3,276	2,518
Provision for bounuses	2,308	2,360
Provision for directors' bounuses	43	122
Provision for loss on business liquidation	1,954	1,954
Notes payable-facilities	3,399	3,249
Other	9,636	11,240
Total current liabilities	189,089	193,767
Noncurrent liabilities		
Bonds payable	34,000	34,000
Convertible bond-type bonds with subscription right s to shares	15,000	15,000
Long-term loans payable	140,380	151,514
Lease obligations	914	1,750
Deferred tax liabilities	1,761	2,035
Provision for retirement benefits	1,987	2,401
Provision for directors' retirement benefits	702	704
Provision for loss on litigation	170	170
Other	1,729	1,603
Total noncurrent liabilities	196,645	209,181
Total liabilities	385,735	402,949
Net assets		
Shareholders' equity		
Capital stock	84,397	84,397
Capital surplus	636	636
Retained earnings	48,389	52,853
Treasury stock	(864)	(864)
Total shareholders' equity	132,558	137,022
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(6,528)	(17,878)
Foreign currency translation adjustment	(16,209)	(16,943)
Total accumulated other comprehensive income	(22,737)	(34,821)
Minority interests	4,129	6,907
Total net assets	113,950	109,108
Total liabilities and net assets	499,686	512,057

(2) [Quarterly Consolidated Statements of Income and Quarterly Consolidated Statement of Comprehensive Income]
 Quarterly Consolidated Statements of Income

(Amount: million yen)

	FY2011 first six months (From April 1, 2011 to September 30, 2011)	FY2012 first six months (From April 1, 2012 to September 30, 2012)
Net sales	102,432	117,280
Cost of sales	72,021	84,866
Gross profit	30,411	32,414
Selling, general and administrative expenses	22,243	26,111
Operating income	8,168	6,303
Non-operating income		
Interest income	257	429
Dividends income	362	861
Other	420	454
Total non-operating income	1,039	1,745
Non-operating expenses		
Interest expenses	1,616	1,712
Foreign exchange losses	2,039	1,253
Equity in losses of affiliates	43	38
Other	388	199
Total non-operating expenses	4,087	3,203
Ordinary income	5,121	4,845
Extraordinary income		
Gain on sales of noncurrent assets	112	30
State subsidy□	86	40
Gain on sales of investment securities	—	4,159
Other	10	83
Total extraordinary income	209	4,313
Extraordinary loss		
Loss on retirement of noncurrent assets	285	65
Loss on valuation of investment securities	675	27
Loss on disaster	1,111	—
Company funeral expenses	—	40
Other	125	47
Total extraordinary losses	2,197	181
Income before income taxes and minority interests	3,132	8,976
Income taxes-current	2,333	2,209
Income taxes-deferred	9	13
Total income taxes	2,342	2,223
Income before minority interests	790	6,753
Minority interests in income	332	145
Net income	457	6,608

[Quarterly Consolidated Statements of Comprehensive Income]

(Amount: million yen)

	FY2011 first six months (From April 1, 2011 to September 30, 2011)	FY2012 first six months (From April 1, 2012 to September 30, 2012)
Income before minority interests	790	6,753
Other comprehensive income		
Valuation difference on available-for-sale securities	(15,666)	(11,351)
Foreign currency translation adjustment	(821)	(806)
Total other comprehensive income	(16,488)	(12,158)
Comprehensive income	(15,697)	(5,404)
Comprehensive income attributable to owners of the parent	(16,013)	(5,477)
Comprehensive income attributable to minority interests	315	72

(3) [Quarterly Consolidated Statements of Cash Flows]

(Amount: million yen)

	FY2011 first six months (From April 1, 2011 to September 30, 2011)	FY2012 first six months (From April 1, 2012 to September 30, 2012)
Net cash provided by (used in) operating activities		
Income before income taxes and minority interests	3,132	8,976
Depreciation and amortization	10,211	9,874
Impairment loss	—	1
Amortization of goodwill	1,147	1,408
Equity in (earnings) losses of affiliates	43	38
Increase (decrease) in allowance for doubtful accounts	7	54
Interest and dividends income	(619)	(1,290)
Interest expenses	1,616	1,712
Foreign exchange losses (gains)	1,175	370
Loss (gain) on sales of investment securities	—	(4,159)
Decrease (increase) in notes and accounts receivable-trade	(4,061)	(5,590)
Decrease (increase) in inventories	(4,126)	(1,898)
Increase (decrease) in notes and accounts payable-trade	940	1,379
Decrease (increase) in other assets	(1,017)	958
Increase (decrease) in other liabilities	(2,949)	(72)
Other loss (gain)	873	20
Subtotal	6,373	11,784
Interest and dividends income received	625	1,044
Interest expenses paid	(1,567)	(1,706)
Other proceeds	130	101
Other payments	(147)	(221)
Income taxes paid	(2,938)	(2,987)
Net cash provided by (use in) operating activities	2,475	8,015
Net cash provided by (used in) investing activities		
Payments into time deposits	(7,162)	(11,094)
Proceeds from withdrawal of time deposits	1,064	14,279
Purchase of investment securities	(14,029)	(9,935)
Proceeds from sales of investment securities	10	5,800
Payments for sales of investments in subsidiaries resulting in change in scope of consolidation	(2,587)	(2,105)
Payments for investments in capital	—	(1,494)
Purchase of noncurrent assets	(12,102)	(15,441)
Proceeds from sales of noncurrent assets	148	45
Payments for retirement of noncurrent assets	(5)	(13)
Proceeds from capital investment subsidies received	33	53
Net decrease (increase) in short-term loans receivable	882	1,813
Payments of loans receivable	(708)	(680)
Collection of loans receivable	23	80
Other payments	(75)	(0)
Other proceeds	—	0
Net cash provided by (use in) investment activities	(34,511)	(18,694)

(Amount: million yen)

	FY2011 first six months (From April 1, 2011 to September 30, 2011)	FY2012 first six months (From April 1, 2012 to September 30, 2012)
Net cash provided by (use in) financial activities		
Net increase (decrease) in short-term loans payable	(3,975)	8,672
Increase (decrease) in commercial papers	—	(10,000)
Proceeds from long-term loans payable	43,870	32,056
Repayment of long-term loans payable	(16,407)	(18,574)
Proceeds from issuance of bonds	979	—
Proceeds from stock issuance to minority shareholders	—	241
Decrease (increase) in treasury stock	(0)	(0)
Repayments of finance lease obligations	(202)	(340)
Cash dividends paid	(1,992)	(1,953)
Cash dividends paid to minority shareholders	(4)	(11)
Net cash provided by (use in) financing activities	22,268	10,091
Effect of exchange rate change on cash and cash equivalents	(384)	(229)
Net increase (decrease) in cash and cash equivalents	(10,152)	(816)
Cash and cash equivalents at beginning of period	78,921	79,449
Increase in cash and cash equivalents from newly consolidated subsidiary	9,266	923
Cash and cash equivalents at end of period	78,035	79,556

(4) Notes Related to Going Concern
N/A

(5) Segment Information

I FY2011 (From April 1, 2011 to September 30, 2011)

1. Sales and Profit by Reportable Operating Segment

(Millions of yen)

	Segment				Other (Note.1)	Total	Adjust- ment (Note.2)	Consolidated Statements of Income (Note.3)
	Medical	Pharma- ceutical	Materials	Total				
Net sales								
(1)Sales to third parties	70,414	18,950	12,930	102,295	137	102,432	—	102,432
(2)Inter-segment sales and transfers	657	9,389	1,708	11,754	22	11,777	(11,777)	—
Total	71,071	28,339	14,639	114,050	159	114,210	(11,777)	102,432
Segment profit	8,386	2,110	1,289	11,786	109	11,895	(3,727)	8,168

(Notes)

1. "Other" is the business segment which is not included in the segment and consist of real estate income and sales by headquarter.
 2. Adjustment for the segment profit of (3,727) million yen includes elimination of inter-segment transaction of (249) million yen and corporate cost of (3,477) million yen. Corporate cost consisted primarily of general and administrative expenses and research and development cost which do not belong to the reporting segment.
 3. Segment profit is adjusted to the operating income on the consolidated statements of income.
2. Information about Impairment Loss on Fixed Assets and Goodwill by Reportable Operating Segment
N/A

II FY2012 (From April 1, 2012 to September 30, 2012)

1. Sales and Profit by Reportable Operating Segment

(Millions of yen)

	Segment				Other (Note.1)	Total	Adjust- ment (Note.2)	Consolidated Statements of Income (Note.3)
	Medical	Pharma- ceutical	Materials	Total				
Net sales								
(1)Sales to third parties	81,380	22,989	12,793	117,163	116	117,280	—	117,280
(2)Inter-segment sales and transfers	620	9,553	1,810	11,984	22	12,007	(12,007)	—
Total	82,000	32,543	14,604	129,148	139	129,287	(12,007)	117,280
Segment profit	7,289	1,428	1,072	9,789	110	9,899	(3,596)	6,303

(Notes)

1. "Other" is the business segment which is not included in the segment and consist of real estate income and sales by headquarter.
2. Adjustment for the segment profit of (3,596) million yen includes elimination of inter-segment transaction of 154 million yen and corporate cost of (3,750) million yen. Corporate cost consisted primarily of general and administrative expenses and research and development cost which do not belong to the reporting segment.
3. Segment profit is adjusted to the operating income on the consolidated statements of income.

2. Change in Reportable Segment

The reportable segment of Nipro Glass India Ltd. and Nipro Tube Glass Ltd. was changed from materials business to medical business from the period ended March 30, 2012 as a result of reconsideration from the view point of global business strategy.

Following this idea, the segment information of the same period of previous year was revised.

3. Information about Impairment Loss of Tangible Assets and Goodwill by Reportable Operating Segment

N/A

(6) Notes to Statements of Shareholder's Equity, if having Significant Variation

N/A